Medtronic : FDA Approves Artificial Intelligence Algorithms For Cardiac Monitoring

美敦力:FDA批准用于心脏监测的人工智能算法

2021-07-28 23:31:25 RTTNews

本文共375个字,阅读需1分钟

U.S. Food and Drug Administration has approved two AccuRhythm AI algorithms for use with the LINQ II insertable cardiac monitor or ICM, Medtronic plc (MDT) said in a statement. AccuRhythm AI applies artificial intelligence (AI) to heart rhythm event data collected by LINQ II, improving the accuracy of information physicians receive so they can better diagnose and treat abnormal heart rhythms. The algorithms address the two most common ICM false alerts - atrial fibrillation (AF), an irregular or rapid rhythm in the upper chambers of the heart; and asystole, a long pause between heartbeats. Medtronic developed the AccuRhythm AI platform and initial algorithms using its proprietary, diverse and debiased database of more than 1 million electrocardiogram heart rhythm episodes. The AccuRhythm AI algorithms will be released on the CareLink Network later this year for use by all implanted LINQ II devices in the United States. For comments and feedback contact: editorial@rttnews.com Business News
美敦力公司(MDT)在一份声明中说,美国食品药品监督管理局已经批准了两种用于LINQ II可插入式心脏监测仪或ICM的AccuRhythm AI算法。 AccuRhythm AI将人工智能(AI)应用于LINQ II收集的心律事件数据,提高医生接收信息的准确性,从而更好地诊断和治疗异常心律。 该算法解决了两种最常见的ICM假警报--心房颤动(AF),在心脏上腔不规则或快速的节律;还有心搏停止,心跳之间长时间的停顿。 美敦力开发了AccuRhythm人工智能平台和初始算法,使用了其专有的、多样化的、具有偏见的100多万个心电图心律事件数据库。 AccuRhythm人工智能算法将于今年晚些时候在CareLink网络上发布,供美国所有植入的LINQ II设备使用。 如需评论和反馈,请联系:editorial@rttnews.com 商业新闻

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文